Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 11/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 10/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 8/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981003 | 0.83 | SSTR4 (0.48) | SSTR4SSTR3SSTR1PGRSSTR2 | |
| SCHEMBL6978458 | 0.81 | PGR (0.47) | PGR | |
| SCHEMBL6976722 | 0.79 | PGR (0.44) | SSTR4SSTR3SSTR1PGR | |
| SCHEMBL6972587 | 0.77 | PGR (0.48) | PGRFNTAFNTB | |
| SCHEMBL6981373 | 0.77 | SSTR4 (0.50) | SSTR4SSTR3SSTR1SSTR2FNTA | |
| SCHEMBL6979415 | 0.77 | TSHR (0.49) | PGRFNTAFNTB | |
| SCHEMBL6982647 | 0.75 | CYP11B1 (0.43) | PGRFNTAFNTB | |
| SCHEMBL6982742 | 0.75 | PGR (0.41) | PGRFNTAFNTB | |
| SCHEMBL6981944 | 0.73 | FNTA (0.48) | FNTAFNTB | |
| SCHEMBL6980086 | 0.73 | TP53 (0.47) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | SSTR4 4554/4885SSTR3 4431/4885SSTR1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.